The core business growth is very strong with 32-37% revenue growth and expanding full-year gross margins. The significant tax benefit is non-recurring, so future quarters will not see this level of net income. However, the robust 2026 guidance suggests continued strong top-line growth, making this a bullish signal for the stock despite the accounting anomaly in net income.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $131.85entry
- T+1 · 9mo ago +2.06%α +2.61% · $134.57
- T+5 · 9mo ago +11.99%α +13.09% · $147.66
- T+20 · 8mo ago −20.27%α −15.03% · $105.13
- T+60 · 6mo ago −48.43%α −55.38% · $68.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TransMedics reported strong fourth quarter and full year 2025 financial results, with revenue up 32% and 37% respectively, driven by increased utilization of its Organ Care System. Net income surged to $105.4 million in Q4 and $190.3 million for the full year, significantly boosted by a one-time $83.8 million tax benefit from the release of a valuation allowance. The company also provided 2026 revenue guidance of $727-$757 million, representing 20-25% growth.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $160.8 million, up 32% YoY from $121.6 million in Q4 2024
- Full year 2025 revenue was $605.5 million, up 37% YoY from $441.5 million in 2024
- Q4 net income was $105.4 million ($2.62 diluted EPS), including an $83.8 million tax benefit
- Full year net income was $190.3 million ($4.87 diluted EPS), including an $82.8 million tax benefit
- 2026 revenue guidance is $727-$757 million, representing 20-25% growth over 2025
- Gross margin was 58% in Q4 2025 (down from 59% in Q4 2024) and 60% for full year 2025 (up from 59% in 2024)
Financial Impact
Revenue growth of 32-37% and 2026 guidance of 20-25% growth indicate strong momentum. The $83.8 million tax benefit significantly inflated Q4 net income, which would have otherwise been $21.6 million.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Net product revenue | $372.4M | +36.0% |
| Service revenue | $233.1M | +39.0% |
Risk Factors
- The substantial net income in Q4 and full year 2025 was heavily influenced by a one-time $83.8 million tax benefit, which is not sustainable
- Gross margin declined slightly in Q4 2025 to 58% from 59% in Q4 2024 due to higher clinical service and freight costs
- Forward-looking statements in the filing highlight numerous risks including regulatory, reimbursement, and execution risks for new programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-066953 |
| Document: tmdx-20260224.htm | 0001193125-26-066953 |
| Document: 0001193125-26-066953-index-headers.html | 0001193125-26-066953 |
| Document: 0001193125-26-066953-index.html | 0001193125-26-066953 |
| Document: 0001193125-26-066953.txt | 0001193125-26-066953 |
| CONTEXT: Previous Earnings (2026-02-24) | 0001193125-26-066953 |
Track record
9 reports on TMDX
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +22.27% at T+60 after the Jun 11, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $90.95 Now $92.21 +1.39% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $88.24 to $91.38 Now $92.21 +4.50% ▲ +3.56% +0.96% vs SPY
- Nov 5, 202611d ago Press Release Bullish 6/10 No price data
- Jun 12, 202622w ago Institutional Cluster Bullish 6/10 Entry $72.91 to $78.79 Now $92.21 +26.47% ▲ +8.06% +7.39% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $73.59 to $73.22 Now $92.21 +25.30% ▼ −0.50% −0.94% vs SPY
- Apr 10, 202631w ago DEFA14A Neutral 3/10 Entry $114.00 to $115.87 Now $92.21 −19.11% ▲ +1.64% −2.86% vs SPY
- Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $147.00 to $134.77 Now $92.21 −37.27% ▼ −8.32% −7.11% vs SPY
- Feb 27, 202637w ago 8-K Neutral 4/10 Entry $145.26 to $129.61 Now $92.21 −36.52% ▼ −10.77% −8.79% vs SPY
- Feb 24, 202637w ago 8-K Bullish 8/10 Viewing Entry $131.85 to $147.66 Now $92.21 −30.06% ▲ +11.99% +13.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers